Avidity Biosciences (RNA)
(Real Time Quote from BATS)
$38.08 USD
+0.74 (1.98%)
Updated Aug 5, 2025 12:30 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Avidity Biosciences, Inc. has a market cap of $4.50B, which represents its share price of $37.34 multiplied by its outstanding shares number of 120.52M. As a mid-cap company, RNA's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
RNA 38.08 +0.74(1.98%)
Will RNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data
Other News for RNA
Avidity Biosciences (RNA) Completes Enrollment for Phase 3 DM1 Treatment Trial
Avidity Biosciences completes enrollment in Phase 3 HARBOR clinical trial
Avidity gets FDA breakthrough therapy status for DMD treatment
Avidity Biosciences (RNA) Secures Breakthrough Therapy Designation from FDA | RNA Stock News